Modified pulmonary surfactant is a potent adjuvant that stimulates the mucosal IgA production in response to the influenza virus antigen

Journal of Immunology

Volumn 176, Issue 2, 2006, Pages 1122-1130

  Mizuno, Dai ^a   Ide Kurihara, Mikiko ^a   Ichinomiya, Tomoko ^a   Kubo, Itsuka ^a   Kido, Hiroshi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; CD40 ANTIGEN; CD86 ANTIGEN; CHOLERA TOXIN B SUBUNIT; CYTOKINE; GLYCOPROTEIN P 15095; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LUNG SURFACTANT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NEUTRALIZING ANTIBODY; SURFACTANT TA; TRANSFORMING GROWTH FACTOR BETA1; VACCINE; VIRUS ANTIGEN; VIRUS HEMAGGLUTININ;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNIZATION; INFLUENZA VIRUS; LYMPHOCYTE; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT MUCOSA;

EID: 30744461365     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.2.1122     Document Type: Article

References (49)

1. Murphy, B. R., and R.G. Webster. 1996. Orthomyxoviruses. In Virology. B. N. Field and D. N. Knipe, eds. Lippincott-Raven, Philadelphia, pp. 1397-1445.
2. Tamura, S. I., H. Asanuma, Y. Ito, Y. Hirabayashi, Y. Suzuki, T. Nagamine, C. Aizawa, T. Kurata, and A. Oya. 1992. Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine. Eur. J. Immunol. 22: 477-481.
3. Waldman, R. H., and R. Ganguly. 1974. Immunity to infections on secretory surfaces. J. Infect. Dis. 130: 419-440.
4. Liew, F. Y., S. M. Russell, G. Appleyard, C. M. Brand, and J. Beale. 1984. Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA Ab rather than serum Ab or cytotoxic T cell reactivity. Eur. J. Immunol. 14: 350-356.
5. Murphy, B. R., and M. L. Clements. 1989. The systemic and mucosal immune response of humans to influenza A virus. Curr. Top. Microbiol. Immunol. 146: 107-116.
6. Renenger, K. B., and P. A. Small, Jr. 1994. Passive immunization: systemic and mucosal. In Handbook of Mucosal Immunology. P. L. Ogra, M. E. Lamm, J. R. McGhee, J. Mestecky, W. Strober, and J. Bienenstock, eds. Academic Press, San Diego, pp. 333-343.
7. Yuki, Y., and H. Kiyono. 2003. New generation of mucosal adjuvants for the induction of protective immunity. Rev. Med. Virol. 13: 293-310.
8. Greenbaum, E., A. Furst, A. Kiderman, B. Stewart, R. Levy, M. Schlesinger, A. Morag, and Z. Zakay-Rones. 2001. Serum and mucosal immunologic responses in children following the administration of a new inactivated intranasal anti-influenza vaccine. J. Med. Virol. 65: 178-184.
9. O'Hagan, D. T., M. L. MacKichan, and M. Singh. 2001. Recent developments in adjuvants for vaccines against infectious diseases. Biomol. Eng. 18: 69-85.
10. Tamura, S., A. Yamanaka, M. Shimohara, T. Tomita, K. Komase, Y. Tsuda, Y. Suzuki, T. Nagamine, K. Kawahara, and H. Danbara. 1994. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine. Vaccine 12: 419-426.
11. Gluck, R., R. Mischler, P. Durrer, E. Purer, A. B. Lang, C. Herzog, and S. J. Cryz, Jr. 2000. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant. J. Infect. Dis. 181: 1129-1132.
12. Wilson, A. D., C. J. Clarke, and C. R. Stokes. 1990. Whole cholera toxin and B subunit act synergistically as an adjuvant for the mucosal immune response of mice to keyhole limpet haemocyanin. Scand. J. Immunol. 31: 443-451.
13. Tamura, S., H. Asanuma, T. Tomita, K. Komase, K. Kawahara, H. Danbara, N. Hattori, K. Watanabe, Y. Suzuki, and T. Nagamine. 1994. Escherichia coli heat-labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine. Vaccine 12: 1083-1089.
14. de, B., A. Zanasi, S. Ragusa, R. Gluck, and C. Herzog. 2002. An open-label comparison of the immunogenicity and tolerability of intranasal and intramuscular formulations of virosomal influenza vaccine in healthy adults. Clin. Ther. 24: 100-111.
15. Durrer, P., U. Gluck, C. Spyr, A. B. Lang, R. Zurbriggen, C. Herzog, and R. Gluck. 2003. Mucosal antibody response induced with a nasal virosome-based influenza vaccine. Vaccine 21: 4328-4334.
16. Mutsch, M., W. Zhou, P. Rhodes, M. Bopp, R. T. Chen, T. Linder, C. Spyr, and R. Steffen. 2004. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350: 896-903.
17. Crouch, E., and J. R. Wright. 2001. Surfactant proteins A and D and pulmonary host defense. Annu. Rev. Physiol. 63: 521-554.
18. Kudo, K., H. Sano, H. Takahashi, K. Kuronuma, S. Yokota, N. Fujii, K. Shimada, I. Yano, Y. Kumazawa, D. R. Voelker, S. Abe, and Y. Kuroki. 2004. Pulmonary collectins enhance phagocytosis of Mycobacterium avium through increased activity of mannose receptor. J. Immunol. 172: 7592-7602.
19. Gurel, O., M. Ikegami, Z. C. Chroneos, and A. H. Jobe. 2001. Macrophage and type II cell catabolism of SP-A and saturated phosphatidylcholine in mouse lungs. Am. J. Physiol. 280: L1266-L1272.
20. Konishi, M., S. Chida, S. Shimada, T. Kasai, Y. Murakami, K. Cho, Y. Fujii, H. Maeta, and T. Fujiwara. 1992. Surfactant replacement therapy in premature babies with respiratory distress syndrome: factors affecting the response to surfactant and comparison of outcome from 1982-86 and 1987-91. Acta Paediatr. Jpn. 34: 617-630.
21. Davenport, F. M., A. V. Hennessy, F. M. Brandon, R. G. Webster, C. D. Barrett, Jr., and G. O. Lease. 1964. Comparisons of serologic and febrile responses in humans to vaccination with influenza A viruses or their hemagglutinins. J. Lab. Clin. Med. 63: 5-13.
22. Smith, P. K., R. I. Krohn, G. T. Hermanson, A. K. Mallia, F. H. Gartner, M. D. Provenzano, E. K. Fujimoto, N. M. Goeke, B. J. Olson, and D. C. Klenk. 1985. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150: 76-85.
23. Hawgood, S., B. J. Benson, and R. L. Hamilton, Jr. 1985. Effects of a surfactant-associated protein and calcium ions on the structure and surface activity of lung surfactant lipids. Biochemistry 24: 184-190.
24. Tanaka, Y., T. Takei, T. Aiba, K. Masuda, A. Kiuchi, and T. Fujiwara. 1986. Development of synthetic lung surfactants. J. Lipid. Res. 27: 475-485.
25. Tanaka, Y., and T. Takei. 1983. Lung surfactants. I. Comparison of surfactants prepared from lungs of calf, ox, dog and rabbit. Chem. Pharm. Bull (Tokyo). 31: 4091-4099.
26. Watanabe, I., Y. Hagiwara, S. E. Kadowaki, T. Yoshikawa, K. Komase, C. Aizawa, H. Kiyono, Y. Takeda, J. R. McGhee, J. Chiba, et al. 2002. Characterization of protective immune responses induced by nasal influenza vaccine containing mutant cholera toxin as a safe adjuvant (CT112K). Vaccine 20: 3443-3455.
27. Tobita, K., A. Sugiura, C. Enomote, and M. Furuyama. 1975. Plaque assay and primary isolation of influenza A viruses in an established line of canine kidney cells (MDCK) in the presence of trypsin. Med. Microbiol. Immunol. 162: 9-14.
28. Asanuma, H., A. H. Thompson, T. Iwasaki, Y. Sato, Y. Inaba, C. Aizawa, T. Kurata, and S. Tamura. 1997. Isolation and characterization of mouse nasal-associated lymphoid tissue. J. Immunol. Methods 202: 123-131.
29. Gonzalez-Juarrero, M., and I. M. Orme. 2001. Characterization of murine lung dendritic cells infected with Mycobacterium tuberculosis. Infect. Immun. 69: 1127-1133.
30. Yang, B., D. F. Yao, M. Ohuchi, M. Ide, M. Yano, Y. Okumura, and H. Kido. 2002. Ambroxol suppresses influenza-virus proliferation in the mouse airway by increasing antiviral factor levels. Eur. Respir. J. 19: 952-958.
31. Sano, H., and Y. Kuroki. 2005. The lung collectins, SP-A and SP-D, modulate pulmonary innate immunity. Mol. Immunol. 42: 279-287.
32. Wright, J. R., and J. A. Clements. 1987. Metabolism and turnover of lung surfactant. Am. Rev. Respir. Dis. 136: 426-444.
33. Poelma, D. L., L. J. Zimmermann, W. A. van Cappellen, J. J. Haitsma, B. Lachmann, and J. F. van Iwaarden. 2004. Distinct effects of SP-B and SP-C on the uptake of surfactant-like liposomes by alveolar cells in vivo and in vitro. Am. J. Physiol. 287: L1056-L1065.
34. Mowat, A. M. 2003. Anatomical basis of tolerance and immunity to intestinal antigens. Nat. Rev. Immunol. 3: 331-341.
35. Yamamoto, M., H. Kiyono, S. Yamamoto, E. Batanero, M. N. Kweon, S. Otake, M. Azuma, Y. Takeda, and J. R. McGhee. 1999. Direct effects on antigen-presenting cells and T lymphocytes explain the adjuvanticity of a nontoxic cholera toxin mutant. J. Immunol. 162: 7015-7021.
36. Cong, Y., C. T. Weaver, and C. O. Elson. 1997. The mucosal adjuvanticity of cholera toxin involves enhancement of costimulatory activity by selective upregulation of B7.2 expression. J. Immunol. 159: 5301-5308.
37. Davis, S. S. 2001. Nasal vaccines. Adv. Drug Deliv. Rev. 51: 21-42.
38. Kehrl, J. H., L. M. Wakefield, A. B. Roberts, S. Jakowlew, M. Alvarez-Mon, R. Derynck, M. B. Sporn, and A. S. Fauci. 1986. Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth. J. Exp. Med. 163: 1037-1050.
39. + T cells requires the coordinate action of interleukin-12 and interferon-γ and is inhibited by transforming growth factor-β. Eur. J. Immunol. 24: 793-798.
40. + Th1/Th2 T cells. Eur. J. Immunol. 30: 2101-2111.
41. Geiser, A. G., J. J. Letterio, A. B. Kulkarni, S. Karlsson, A. B. Roberts, and M. B. Sporn. 1993. Transforming growth factor β1 (TGF-β1) controls expression of major histocompatibility genes in the postnatal mouse: aberrant histocompatibility antigen expression in the pathogenesis of the TGF-β1 null mouse phenotype. Proc. Natl. Acad. Sci. USA 90: 9944-9948.
42. Takeuchi, M., P. Alard, and J. W. Streilein. 1998. TGF-β promotes immune deviation by altering accessory signals of antigen-presenting cells. J. Immunol. 160: 1589-1597.
43. Fukaura, H., S. C. Kent, M. J. Pietrusewicz, S. J. Khoury, H. L. Weiner, and D. A. Hafler. 1996. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-β1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J. Clin. Invest. 98: 70-77.
44. Iijima, H., I. Takahashi, and H. Kiyono. 2001. Mucosal immune network in the gut for the control of infectious diseases. Rev. Med. Virol. 11: 117-133.
45. Cazac, B. B., and J. Roes. 2000. TGF-β receptor controls B cell responsiveness and induction of IgA in vivo. Immunity 13: 443-451.
46. Coffman, R. L., B. W. Seymour, D. A. Lebman, D. D. Hiraki, J. A. Christiansen, B. Shrader, H. M. Cherwinski, H. F. Savelkoul, F. D. Finkelman, and M. W. Bond. 1988. The role of helper T cell products in mouse B cell differentiation and isotype regulation. Immunol. Rev. 102: 5-28.
47. Allison, A. C., J. C. Lee, and E. M. Eguchi. 1995. Pharmacological regulation of the production of inflammatory cytokines TNF-α and IL-1-β. In Human Cytokines: Their Role in Disease and Therapy. B. Aggarwal and R. K. Puri, eds. Blackwell Science Oxford, pp. 689-713.
48. Maino, V. C., and L. J. Picker. 1998. Identification of functional subsets by flow cytometry: intracellular detection of cytokine expression. Cytometry 34: 207-215.
49. van Iwaarden, J. F., E. Claassen, S. H. Jeurissen, H. P. Haagsman, and G. Kraal. 2001. Alveolar macrophages, surfactant lipids, and surfactant protein B regulate the induction of immune responses via the airways. Am. J. Respir. Cell. Mol. Biol. 24: 452-458.